On July 1st, a new partnership launched in the fight against antimicrobial resistance. GNA NOW (Gram-Negative Antibacterials NOW) will work on the development of novel antibacterial agents against antimicrobial resistance in gram-negative bacteria. The project is a multi-stakeholder effort, led by Evotec and managed by Lygature, with other partners from academia, industry and SMEs: Nosopharm, BIOASTER, Helmholtz Centre for Infection Research, North Bristol National Health Service Trust, University of Liverpool, Inserm, Erasmus Medical Center, Medical University of Vienna, and Fraunhofer IME.
Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB.
An international consortium of research groups aims to develop novel antibiotics against the tuberculosis bacteria and two other deadly bacteria. The European Union has awarded a total of EUR 18 million to the RespiriTB and RespiriNTM projects. Researchers from the Leiden University Medical Centre (LUMC) will be taking part in the study, that is set to last six years.
AGILeBiotics has been awarded a Lead Development Voucher by the Netherlands Antibiotic Development Platform (NADP). The total amount of €50.000 will be allocated to the pre-clinical R&D activities. With this financial support the company will test its antibiotic candidates in a clinically relevant animal model of infection. The next goal is the nomination of an antibiotic candidate for pre-clinical development.
ZonMw (the Netherlands Organisation for Health Research and Development) is performing, on behalf of JPIAMR and the recently started consortium VALUE-Dx, a survey on resources (collections of biological material and databases) that are relevant for antimicrobial resistance (AMR) research. In parallel, they collect information about services that are provided by research infrastructures and some biobanks.
The Second Ministerial Conference on Antimicrobial Resistance (AMR) will take place in Grand Hotel Huis ter Duin, in the historic town of Noordwijk. Here, in this venue at sea, participant will explore what has been done since the first meeting that was organised five years ago, and to take further steps to accelerate the implementation of the Global Action Plan on AMR. For two days, working closely together with the World Health Organization (WHO), Food and Agriculture Organization (FAO) and World Organisation for Animal Health (OIE), participants will look back at recent global developments and explore new ways to work jointly to tackle the threat of antimicrobial resistance.